Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND PLUS oral semaglutide cardiovascular outcomes trial in type 2 diabetes
ISRCTN76193287Phase 4Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide with Placebo (2 arms). Primary endpoint: Expanded major adverse cardiovascular events. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN76193287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76193287.